PL414266A1 - Concentration of selenium in blood as a risk factor for cancers in women - Google Patents

Concentration of selenium in blood as a risk factor for cancers in women

Info

Publication number
PL414266A1
PL414266A1 PL414266A PL41426615A PL414266A1 PL 414266 A1 PL414266 A1 PL 414266A1 PL 414266 A PL414266 A PL 414266A PL 41426615 A PL41426615 A PL 41426615A PL 414266 A1 PL414266 A1 PL 414266A1
Authority
PL
Poland
Prior art keywords
concentration
selenium
cancers
women
blood
Prior art date
Application number
PL414266A
Other languages
Polish (pl)
Inventor
Jan Lubiński
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL414266A priority Critical patent/PL414266A1/en
Publication of PL414266A1 publication Critical patent/PL414266A1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Sposób określania ryzyka raka, charakteryzuje się tym, że obejmuje ocenę stężenia selenu w próbce biologicznej badanej kobiety, przy czym stężenie selenu wskazuje znacząco zwiększone lub zmniejszone ryzyko rozwoju raków oraz uznaje się, że ryzyko raków: przy stężeniu selenu w surowicy ? 70 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy) jest podwyższone, zaś przy stężeniu selenu w surowicy 70 - 90 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy) jest obniżone.The method of determining the risk of cancer is characterized in that it includes the assessment of the selenium concentration in the biological sample of the examined woman, with the selenium concentration indicating a significantly increased or reduced risk of developing cancers and it is recognized that the risk of cancer: at serum selenium concentration? 70 µg / l (or the concentration in any biological material corresponding to the serum concentration) is increased, and at a serum selenium concentration 70 - 90 µg / l (or the concentration in any biological material corresponding to the serum concentration) is reduced.

PL414266A 2015-10-05 2015-10-05 Concentration of selenium in blood as a risk factor for cancers in women PL414266A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL414266A PL414266A1 (en) 2015-10-05 2015-10-05 Concentration of selenium in blood as a risk factor for cancers in women

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL414266A PL414266A1 (en) 2015-10-05 2015-10-05 Concentration of selenium in blood as a risk factor for cancers in women

Publications (1)

Publication Number Publication Date
PL414266A1 true PL414266A1 (en) 2017-04-10

Family

ID=58463572

Family Applications (1)

Application Number Title Priority Date Filing Date
PL414266A PL414266A1 (en) 2015-10-05 2015-10-05 Concentration of selenium in blood as a risk factor for cancers in women

Country Status (1)

Country Link
PL (1) PL414266A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL422751A1 (en) * 2017-09-05 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women, depending on their age and concentration of chosen microelements

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL422751A1 (en) * 2017-09-05 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women, depending on their age and concentration of chosen microelements

Similar Documents

Publication Publication Date Title
MX389083B (en) Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging.
CL2019002264A1 (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging.
MX383381B (en) METHODS AND COMPOSITIONS FOR DETECTING MISFOLDED PROTEINS.
EP4273551A3 (en) Multiplexed total antibody and antibody-conjugated drug quantification assay
MX384485B (en) EARLY DETECTION OF PREECLAMPSIA.
MX2015015023A (en) Method for determining free copper.
NZ720608A (en) Β-glucan assay methods
PL414266A1 (en) Concentration of selenium in blood as a risk factor for cancers in women
PL414265A1 (en) Concentration of copper in blood as a risk factor for extramammary breast cancers in women
PL415634A1 (en) Concentration of selenium in blood as a risk factor for cancers in men
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
PL415644A1 (en) Concentration of iron in blood as a risk factor for cancers in women after the age of 50
PL415640A1 (en) Concentration of iron in blood and changes within HFE gene as risk factors for cancers in women
PL415636A1 (en) Concentration of iron in blood as a risk factor for cancers in men
PL415632A1 (en) Concentration in blood and changes within IL6 gene as risk factors for cancers in women
PL439313A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood
PL415643A1 (en) Concentration of iron in blood and changes within GPX1 gene as risk factors for cancers in women
PL414267A1 (en) Concentration of iron in blood as a risk factor for cancers in women who are carriers of a mutation in BRCA1 gene
PL415646A1 (en) Concentration of copper in blood and changes within CAT gene as risk factors for cancers in women
PL407244A1 (en) Electrochemical bio-sensor for detecting S100B protein
PL415645A1 (en) Concentration of zinc in blood and changes within MMP1 gene as risk factors for cancers in women
PL415639A1 (en) Concentration of iron in blood and changes within SEP15 gene as risk factors for cancers in women
PL439314A1 (en) Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood
PL414268A1 (en) Concentration of zinc in blood within IL6 gene as risk factors for cancers in women
PL439317A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations